Daiichi Sankyo has claimed approval in Japan, its home market, for TROP2-targeting antibody-drug conjugate (ADC) datopotamab ...

Opdivo Qvantig (nivolumab and hyaluronidase) has been approved for use across almost all of Opdivo's lengthy list of ...

It was the day we’d all been waiting for. Rachel Reeves’ Autumn Budget felt like it had been on the horizon for a while. And it was great to see a commitment to the NHS, with an extra £22.6 ...

Another clinical trial has found that SIGA Technologies' antiviral drug tecovirimat is ineffective as a treatment for mpox, prompting the investigators to stop patient recruitment. The study by ...

Prominent podcaster Steven Bartlett has been accused of allowing misleading health information to be shared on his Diary of a CEO stream, which has millions of subscribers. A BBC investigation ...

Four years after buying exclusive US rights to GAIA's digital therapeutic to help people with depression, Swedish drugmaker Orexo has terminated the deal. Deprexis is an online cognitive ...

This month, we explore the 125-year-old history of Abbott Laboratories and its most significant milestone to date – the creation of its own independent company, AbbVie. In 1888, a 30-year-old ...

A new study has confirmed that the rate of colorectal cancer is rising in younger adults around the world, with England among the countries seeing the highest increase. The paper in The Lancet ...

It’s no secret that drug development is a huge gamble for pharmaceutical companies. The process involves betting billions of dollars and more than a decade of time that a compound will beat the ...

A federal appeals court in the US has declined to overturn an attempt by Novartis to block the launch of a generic version of its blockbuster heart failure drug Entresto. The US Court of Appeals ...

Venture capital group Abingworth is reportedly trying to raise up to $1.5 billion in investment funding to support biopharma companies' clinical development programmes in return for royalties on ...

GSK's BCMA-directed antibody-drug conjugate Blenrep reduced the risk of death by 42% in a multiple myeloma trial that the company believes could be practice-changing. The DREAMM-7 study showed ...